NRAS and acute myeloid leukemia: Since OCI-AML3 cells also contain a homozygous, gain of function mutation, NRAS-Q61L, our findings also suggest that a combination of MI and venetoclax or abemaciclib may also have superior activity against NPM1/RAS-mutated AML cells [27].